OptiBiotix Health (LON:OPTI) Sets New 1-Year Low – What’s Next?

OptiBiotix Health Plc (LON:OPTI)’s stock price reached a new 52-week low during trading on Thursday . The company traded as low as GBX 6.50 and last traded at GBX 6.99, with a volume of 118340 shares. The stock had previously closed at GBX 6.75.

OptiBiotix Health Trading Up 3.5%

The company has a 50-day moving average of GBX 8.03 and a 200-day moving average of GBX 10.14. The firm has a market capitalization of £7.22 million, a price-to-earnings ratio of -232.83 and a beta of 1.71.

OptiBiotix Health (LON:OPTI) last released its earnings results on Tuesday, September 16th. The company reported GBX (1.15) earnings per share for the quarter. OptiBiotix Health had a negative net margin of 524.43% and a negative return on equity of 36.76%.

Insider Transactions at OptiBiotix Health

In other OptiBiotix Health news, insider Stephen O’Hara acquired 95,238 shares of the stock in a transaction that occurred on Tuesday, September 23rd. The stock was acquired at an average price of GBX 11 per share, with a total value of £10,476.18. Also, insider David Blain bought 84,053 shares of the business’s stock in a transaction on Wednesday, October 1st. The stock was acquired at an average cost of GBX 1,175 per share, for a total transaction of £987,622.75. In the last ninety days, insiders have purchased 229,291 shares of company stock valued at $100,309,893. Insiders own 26.82% of the company’s stock.

About OptiBiotix Health

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome – the collective genome of the microbes in the body – in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements.